A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Using gefitinib or Osimertinib, an EGFR tyrosine kinase inhibitor (TKI), in patients with
active mutations in epithelial cell growth factor receptors (EGFR), 70% response rate (CR+PR)
and 90% disease control rate (CR+PR+SD) compared to the current non-small cell therapy, which
is significant in the EFRT treatment. However, resistance causes recurrence in most patients.
Therefore, it is necessary to develop a more effective treatment. Recently, in Japan,
combined allotinib and bevacizumab therapy as primary therapy in non-small cell lung cancer
patients with EGFR mutation improved PFS statistically significantly compared to allotinib
monotherapy, suggesting the possibility of a new treatment (Hazard ratio 0.605, 95% CI
0.417-0.877, P=0.016). In addition, subsequent osmutinib and bevacizumab combination therapy
showed a significant difference in PFS in the smoker group, although they did not show
significant improvement in PFS in the entire patient group. (Hazard ratio 0.605, 95% CI
0.417-0.877, P=0.016). Since EGFR mutated lung cancer is highly frequent in Korea, it is
necessary to develop more effective treatments for such patients. Therefore, we propose this
clinical trial to find out the efficacy of lasertinib and bevacizumab combination therapy.